Nublexa
(Orelabrutinib)Phase 3Small molecule
It is used to treat certain types of blood cancers, specifically chronic lymphocytic leukemia and marginal zone lymphoma. It works by blocking a protein that helps cancer cells grow and survive.[1] Nublexa is currently being investigated across 25 indications[3], with its most advanced program in Phase 3.[1]
Nublexa is one of 390 small molecule programs targeting Neuromyelitis Optica. It is currently in Phase 3.
25
Indications
63
Total Trials
40
Active Trials
389
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 25 indications
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Zofran
NovartisPreclinical
Cabenuva
GSKPreclinical
Norvir
AbbViePreclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma7 trials
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Recruiting·—·Phase 4·NCT07355699·88 enrolled
Show 4 more trials
Mantle Cell Lymphoma5 trials
Treatment5 trials
Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL
Active, not recruiting·—·Phase 2·NCT07480863·65 enrolled
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Recruiting·—·Phase 2·NCT06530511·30 enrolled
Show 2 more trials
Central Nervous System Lymphoma4 trials
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05600660·28 enrolled
Show 1 more trial
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04961515·19 enrolled
Newly Diagnosed4 trials
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07208981·169 enrolled
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05322733·25 enrolled
32 more indications
Immune Thrombocytopenia3 trials
Methotrexate2 trials
MALT lymphoma2 trials
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07247383·39 enrolled
Primary Central Nervous System Lymphoma2 trials
Mantle Cell Lymphoma (MCL)2 trials
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study of Orelabrutinib in Combination With Obinutuzumab and Short-course Venetoclax in Patients With Treatment-naïve Mantle Cell Lymphoma (MCL)
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07719556·39 enrolled
Chronic Lymphocytic Leukemia1 trial
Cardiac Repolarization1 trial
Monotherapy1 trial
Pomalidomide1 trial
Relapsing-Remitting Multiple Sclerosis1 trial
Efficacy and Safety1 trial
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled
Lenalidomide1 trial
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07448324·50 enrolled
Follicular Lymphoma1 trial
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial
Randomized1 trial
Neuromyelitis Optica1 trial
Systemic Lupus Erythematosus1 trial
Tyrosine Kinase Inhibitor1 trial
Hepatic Impairment1 trial
Cohort Study1 trial
Autologous Hematopoietic Stem Cell Transplantation1 trial
Multiple Sclerosis (MS) Primary Progressive1 trial
Follicular Lymphoma (FL)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Orelabrutinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details